Research & Reviews: Journal of Nursing & Health Sciences

A Student Note on Cardiovascular Diseases

Siva ManiMala Y[1]*, Sanjana Gautam[1], Goutham Reddy B[2]

[1]Department of Pharmacy, Vignan Institute of Pharmaceutical Technology, Visakhapatnam, Andhra Pradesh, India

[2]Department of Engineering, Pydah College of Engineering and Technology, Visakhapatnam, Andhra Pradesh, India

Review Article

Received date: 16/08/2016

Accepted date: 17/08/2016

Published date: 24/08/2016

***For Correspondence**

Siva ManiMala Y, Department of Pharmacy, Vignan Institute of Pharmaceutical Technology, Visakhapatnam, Andhra Pradesh, India, Tel: 8519939610.

E-mail: ysmanimala94@gmail.com

Keywords: Cardiovascular diseases, Diabetes, Cardiovascular risk.

ABSTRACT

Cardiovascular Diseases (CVDs) remain the greatest reason for deaths around the world. More than 17 million individuals has died suffering from CVDs consistently. More than 3 million of these deaths happened before the age of 60 and could have to a great extent been counteracted. The rate of unexpected losses from CVDs ranges from 4% in developed countries and 42% in under developed countries.

INTRODUCTION

Cardiovascular infections (CVDs) are a gathering of disorders of the heart and veins. It incorporates coronary illness, cerebrovascular infection, rheumatic coronary illness, profound vein thrombosis and embolism [1-3].

CVD is a class of infections that include the heart and veins. Cardiovascular sickness incorporates coronary supply route illnesses (CAD, for example, angina and myocardial dead tissue. Different CVDs are stroke, hypertensive coronary illness, cardiomyopathy, heart arrhythmia, valvular coronary illness, carditis, aortic aneurysms and venous thrombosis [4,5].

RISK FACTORS

Risk factors include: Age, sexual orientation, tobacco use, physical dormancy, exorbitant liquor utilization, undesirable eating routine, weight, family history of cardiovascular ailment, raised circulatory strain (hypertension), raised glucose (diabetes mellitus), raised blood cholesterol, psychosocial elements, destitution and low instructive status, and air contamination [6-8]. Some of these danger elements, for example, age, sexual orientation or family history, hereditary, are unchanging; in any case, numerous vital cardiovascular danger elements are modifiable by way of life change, hyperlipidemia, and diabetes [2,9,10].

Some danger variables are more hazardous than others. For instance, smoking likely causes a more serious danger to wellbeing than heftiness does. Likewise, chance variables associate [11,12]. Along these lines, on the off chance that you have two or more hazard variables, your wellbeing danger is significantly more expanded than if you simply have one. For instance, an Oxford study observed that men matured 50 who smoke, have elevated cholesterol and have (hypertension), kick the bucket, by and large, 10 years sooner than men who don't have these danger components [8,13,14].

RISK ASSESSMENT

Existing cardiovascular sickness or a past cardiovascular occasion, for example, a heart assault or stroke, is the most grounded indicator of a future cardiovascular occasion [15-18]. Age, sex, smoking, circulatory strain, blood lipids and diabetes are vital indicators of future cardiovascular ailment in individuals who are not known not cardiovascular malady. These measures, and now and again others, might be joined into composite danger scores to evaluate an individual's future danger of cardiovascular ailment. Various danger scores exist despite the fact that their particular benefits are faced off regarding [1,5,9,19-21]. Other indicative tests and biomarkers stay under assessment however at present these need obvious confirmation to bolster their standard use. They incorporate family history, coronary supply route calcification score, high affectability C-responsive protein (hs-CRP), lower leg brachial list, lipoprotein subclasses and molecule fixation, lipoprotein(a), apolipoproteins An I and B, fibrinogen, white platelet number, homocysteine, N-terminal ace B-sort natriuretic peptide (NT-proBNP) and markers of kidney capacity [22,23].

PATHOPHYSIOLOGY OF CARDIOVASCULAR DISEASE

Atherosclerosis is the significant reason for cardiovascular sickness. Hypercholesterolaemia, hypertension and cigarette smoking are the normal danger components for atherosclerosis [24-28]. These danger variables join behind a union of component, including oxidation and irritation in the conduit divider that, with time, offers ascend to trademark greasy stringy sores. Physical injury and irritation produce sore break, which can prompt clinical occasions, for example, heart assault and stroke, or resolve with plaque development. Sickness movement is set apart by the incendiary marker CRP (C-responsive protein) [2,5,8,29]. Coronary atherosclerosis is the normal reason for heart disappointment (HF). Scattered calcium motioning to the myofilaments happens in HF and in cardiomyopathy. Upgraded calcium flagging smothers HF. Neuro-humoral and biomechanical forms, as found in hypertension, produce cardiovascular hypertrophy, which inclines to HF through apoptosis [30]. In spite of the fact that in people cardiovascular harm produces changeless loss of cells, in light of the fact that the heart cannot recover, advancements in undifferentiated organism innovation propose that assistance is close by [31].

SYMPTOMS

Cardiovascular disease is created by limited, blocked or hardened veins that keep your heart, mind or different parts of your body from sufficiently accepting blood. Cardiovascular sickness side effects might be distinctive for men and ladies [32-35].

The most well-known side effect of coronary course is angina, or mid-section torment [36]. Angina can be portrayed as an inconvenience, greatness, weight, hurting, copying, totality, pressing, or difficult feeling in your mid-section. It can be mixed up for acid reflux or indigestion. Angina may likewise be felt in the shoulders, arms, neck, throat, jaw or back [37,38].

Cardiomyopathy is the agglomeration and solidifying of affection muscle. In aboriginal phases of cardiomyopathy, you may accept no indications. As the action exacerbates, manifestations may include:

- Shortness of animation with accomplishment or actual still
- Swelling of the legs, lower legs and anxiety
- Weakness
- Sporadic heartbeats that vibe quick, assault or clashing
- Tipsiness, blackout and blacking out

PREVENTION

Most hazard elements for cardiovascular sickness (CVD) are connected, which implies that in the event that you have one danger variable, you will presumably have others [15,18,22,39]. For instance, individuals who drink intensely for the most part have terrible eating routines and will probably smoke. Hefty individuals are likewise more prone to have other issue.

Tending to one danger element, for example, surrendering smoking, will bring critical medical advantages, yet to fundamentally lessen your danger of creating CVD, you have to take a gander at your way of life overall [40,41].

MEDICATION OF CVD

There is an assortment of medications recommended for patients with coronary illness. It's essential for both patients living with coronary illness and the individuals who administer to them to comprehend the recommended pharmaceutical, to take after the headings of use, and to have the capacity to perceive the conceivable reactions connected with the medication [25,28,31,40-45].

Medicine Includes: ACE Inhibitors, Aldosterone Inhibitor, Angiotensin II Receptor Blocker, Beta-Blockers, Calcium Channel Blockers and Diuretics [46,47].

EPIDEMIOLOGY

As of late, the strength of interminable sicknesses as significant supporters to add up to worldwide mortality has risen and has been already depicted in subtle element somewhere else [48]. By 2005, the aggregate number of cardiovascular malady (CVD) passings (principally coronary illness, stroke, and rheumatic coronary illness) had expanded internationally to 17.5 million [24,49,50]. Of these, 7.6 million were ascribed to coronary illness and 5.7 million to stroke. More than 80 percent of the passings happened in low and center salary nations (WHO, 2009e). The World Health Organization (WHO) gauges there will be around 20 million CVD passings in 2015, representing 30 percent of all passings around the world (WHO, 2005) [51-55]. By 2030, scientists extend that non-transferable sicknesses will represent more than 75% of passings around the world; CVD alone will be in charge of a greater number of passings in low wage nations than irresistible illnesses (counting HIV/AIDS, tuberculosis, and jungle fever), maternal and perinatal conditions, and dietary issue joined. Hence, CVD is today the biggest single donor to worldwide mortality and will keep on dominating mortality patterns later on (WHO, 2009e) [29,36,52,54-59].

TREATMENT

Treatment for coronary illness (CHD) more often than not is the same for both ladies and men. Treatment may incorporate way of life changes, medications, restorative and surgical systems, and cardiovascular (recovery) [41,60-62].

The objectives of treatment are to:

- Diminish manifestations.
- Lessen hazard elements with an end goal to moderate, stop, or turn around the development of plaque.
- Bring down the danger of blood clumps framing. (Blood clumps can bring about a heart assault.)
- Enlarge or sidestep plaque-obstructed coronary (heart) supply routes.
- Counteract CHD inconveniences.

ONGOING RESEARCHES ON CVD

CVD keeps on being the main source of death in the US. Around 1,400,000 individuals kick the bucket from cardiovascular ailment every year. The American Heart Association evaluates that 2,600 Americans bite the dust of cardiovascular disease consistently [63-81]. At Johns Hopkins, personnel with a specific enthusiasm for cardiovascular sickness are drawing nearer both essential and auxiliary aversion modalities in high hazard populaces, incorporating families with untimely coronary infection, individuals with hypertension as well as heftiness, and an urban group populace [58,63,79,82-93]. Examines range from hereditary and sub-atomic investigations. We likewise have an expansive enthusiasm for the connection in which intercession and counteractive action methodologies are utilized, including medicinal situations, elective consideration frameworks in groups, and self-improvement. An extensive segment of our work is centered around hereditary the study of disease transmission and quality environment associations [89,92,94-100].

REFERENCES

1. Kisters K, et al. Magnesium metabolism, vitamin D and interleukins in cardiovascular disease. Metabolomics. 2016;6:177.
2. Hickey A, et al. Cardiovascular disease risk assessment tools in HIV-infected patients - Are they adequate? J AIDS Clin Res. 2016;7:583.
3. Altura BM, et al. Genotoxic effects of magnesium deficiency in the cardiovascular system and their relationships to cardiovascular diseases and atherogenesis. J Cardiovasc Dis Diagn. 2016;S1:008.
4. Afroz R, et al. Honey-derived flavonoids: Natural products for the prevention of atherosclerosis and cardiovascular diseases. Clin Exp Pharmacol. 2016;6:208.
5. Ritchey MD, et al. Million hearts: Prevalence of leading cardiovascular disease risk factors--United States, 2005-2012. Morbidity and Mortality Weekly Report. 2014;63:462-467.
6. Gillespie CD, et al. Coronary heart disease and stroke deaths—United States, 2009. Morbidity and Mortality Weekly Report Supplement-CDC Health Disparities and Inequalities Report—United States. 2013;62:157-160.
7. World Health Organization. 2008-2013 action plan for the global strategy for the prevention and control of non-communicable diseases: Prevent and control cardiovascular diseases, cancers, chronic respiratory diseases and diabetes. 2009.
8. De Backer G, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention & Rehabilitation. 2003;10:S1-S78.

9. Yusuf S, et al. Global burden of cardiovascular diseases part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.

10. Thavendiranathan P, et al. Primary prevention of cardiovascular diseases with statin therapy: A meta-analysis of randomized controlled trials. Archives of Internal Medicine. 2006;166:2307-2313.

11. Manach C, et al. Polyphenols and prevention of cardiovascular diseases. Current opinion in lipidology. 2005;16:77-84.

12. Adekunle R, et al. Review of cardiovascular disease in HIV infected women. J AIDS Clin Res. 2016;7:557.

13. Maksimovich IV. Transcatheter cerebral revascularization in the treatment of atherosclerotic lesions of the brain. Brain Disord Ther. 2016;5:209.

14. Sandhu H. Cardiovascular diseases associated with pregnancy: Early assessment using non-invasive microRNA profiling. Clinics Mother Child Health. 2015;12:212.

15. Zafar R. A new insight into pathogenesis of cardiovascular diseases: Stress induced lipid mediated, vascular diseases. J Cardiovasc Dis Diagn. 2015;3:206.

16. Deleskog A, et al. Vitamin D and aspects of cardiovascular disease. J Diabetes Metab. 2015;6:545.

17. Charkha N, et al. Estimating risk of mortality from cardiovascular diseases using negative binomial regression. Epidemiol. 2013;3:127.

18. Yang D, et al. An evolutionary perspective on cardiovascular disease. J Phylogen Evolution Biol. 2013;1:e103.

19. Ritu M, et al. Blood homocystiene and lipoprotein (A) levels, stress and faulty diet as major risk Factors for early cardiovascular diseases in Indians. J Cardiovasc Dis Diagn. 2014;2:163.

20. Hubert HB, et al. Obesity as an independent risk factor for cardiovascular disease: A 26 year follow-up of participants in the Framingham Heart Study. Circulation. 1983;67:968-977.

21. Winkleby MA, et al. Socioeconomic status and health: How education, income and occupation contribute to risk factors for cardiovascular disease. American Journal of Public Health. 1992;82:816-820.

22. Murray CJ, et al. Global mortality, disability and the contribution of risk factors: Global burden of disease study. The Lancet. 1997;349:1436-1442.

23. Lopez AD, et al. Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. The Lancet. 2006;367:1747-1757.

24. Han C, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. The Journal of Rheumatology. 2006;33:2167-2172.

25. Anderson KM, et al. Cardiovascular disease risk profiles. American Heart Journal. 1991;121:293-298.

26. Pearson TA, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-391.

27. Lee IM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The women's health study: A randomized controlled trial. JAMA. 2005;294:56-65.

28. Grundy SM, et al. Guide to primary prevention of cardiovascular diseases a statement for healthcare professionals from the task force on risk reduction. Circulation. 1997;95: 2329-2331.

29. Strandberg TE, et al. Long-term mortality after 5 year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA. 1991;266:1225-1229.

30. Nakamura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. The Lancet. 1991;368:1155-1163.

31. Taylor F, et al. Statins for the primary prevention of cardiovascular disease. The Cochrane Library. 2013.

32. Downs JR, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.

33. Cai H, et al. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circulation research. 2000;87:840-844.

34. Stoll DP, et al. The importance of psychological assessment and support in patients suffering from cardiovascular disease or undergoing cardiac treatment. J Cardiovasc Dis Diagn. 2014;2:161.

35. Smith JK. Exercise and atherosclerotic cardiovascular disease. Intern Med. 2014;S11:003.

36. Fleming JA, et al. Dietary patterns that decrease cardiovascular disease and increase longevity. J Clin Exp Cardiolog. 2013;S6:006.

37. Calderon Artero P, et al. Fish oil metabolites: Translating promising findings from bench to bedside to reduce cardiovascular disease. J Glycom Lipidom. 2012;2:104.

38. Memon AG, et al. Correlation of glycated hemoglobin (HbA1c) with different cardiovascular risk factors in non-diabetic patients. J Cardiovasc Dis Diagn. 2016;4:243.

39. Sofi F, et al. Consumption of buckwheat products and cardiovascular risk profile: A randomized, single-blinded crossover trial. J Nutr Food Sci. 2016;6:501.

40. Scatigna M. Cardiovascular risk and physical activity: Simulated analysis in general practice patients based on a risk score system. Primary Health Care. 2016;6:219.

41. Braber TL, et al. Reproducibility and impact of CT-scanning on pulse wave velocity measurement for cardiovascular risk stratification in an asymptomatic population. Angiol. 2016;4:167.

42. Jacques M, et al. Impact of cardiovascular risk in elderly physical activity program participants. J Gerontol Geriatr Res. 2015;4:246.

43. Mann MC. Vitamin D deficiency and cardiovascular risk: We're still in the dark. J Nutr Food Sci. 2015;5:418.

44. Reis RK, et al. Cardiovascular risk in people living with HIV/AIDS: Implications for health care. J AIDS Clin Res. 2015;6:513.

45. Lozanov LB, et al. Comorbidity of obesity and thyroid dysfunction: An association with greater cardiovascular risk factors. Biol syst Open Access. 2015;4:142.

46. Arad Y, et al. Adrenal cortisol hyper-responsiveness as a possible cause of obesity, insulin resistance and cardiovascular risk. J Diabetes Metab. 2015;6:608.

47. Al-Dohan JA, et al. The relation between trace elements levels and some cardiovascular risk factors in patients with obstructive coronary artery disease in Basra. Biol Med. 2015;S3:010.

48. Roever L, et al. The cut-off values of epicardial fat in metabolic syndrome, cardiovascular risk factors, coronary and carotid stenosis. J Metabolic Synd. 2015;4:e116.

49. Hassan MM, et al. Dyslipidemia: A cardiovascular risk factor in type 1 diabetes and its correlations. J Diabetes Metab. 2015;6:586.

50. Adu EM, et al. Assessment of cardiovascular risk indices in type 2 diabetes mellitus. Trop Med Surg. 2015;3:184.

51. Ramachandran A, et al. Hyp-O-besity: Unmet challenge in management of type 2 diabetes mellitus and cardiovascular risk. J Diabetes Metab. 2015;6:520.

52. Farrag A, et al. Obesity and other cardiovascular risk factors in Egyptian university students: magnitude of the problem. Epidemiology (Sunnyvale). 2015;5:181.

53. Sans S, et al. The burden of cardiovascular diseases mortality in Europe. European Heart Journal. 1997;18:1231-1248.

54. Danesh J, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. JAMA: The Journal of the American Medical Association. 2005;294:1799-1809.

55. Sin DD, et al. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003;107:1514-1519.

56. Rydén L, et al. Guidelines on diabetes, pre-diabetes and cardiovascular diseases: Full text. European Heart Journal Supplements. 2007;9:C3-74.

57. Stone PH, et al. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Annals of Internal Medicine. 1980;93:886-904.

58. Stamler J, et al. Blood pressure, systolic and diastolic and cardiovascular risks: US population data. Archives of Internal Medicine. 1993;153:598-615.

59. Stentz FB, et al. Pro-inflammatory cytokines, markers of cardiovascular risks, oxidative stress and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079-2086.

60. Goodman E, et al. Factor analysis of clustered cardiovascular risks in adolescence obesity is the predominant correlate of risk among youth. Circulation. 2005;111:1970-1977.

61. Henderson DC, et al. Clozapine, diabetes mellitus, hyperlipidemia and cardiovascular risks and mortality: results of a 10 year naturalistic study. Journal of Clinical Psychiatry. 2005;66:1116-1121.

62. Ogihara T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51:393-398.

63. Hokanson JE, et al. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. Journal of Cardiovascular Risk. 1996;3:213-219.

64. Staessen JA, et al. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. Journal of hypertension. 2003;21:1055-1076.

65. Mahmood D. Management of residual cardiovascular risk in dyslipidaemic patient with metabolic syndrome. Gen Med (Los Angel). 2015;3:163.

66. Pasha EP, et al. Ethnoracial disparities in Alzheimer's disease: Target on cardiovascular risks via lifestyle changes? J Gerontol Geriat Res. 2014;3:128.

67. Cowart JB, et al. Perioperative management of cardiovascular risk in vascular surgery patients: What's new in 2014? J Vasc Med Surg. 2014;2:168.

68. Pasqualetti G, et al. Cardiovascular risk and mild thyroid hormone deficiency: Are there some differences in the elderly? J Hematol Thrombo Dis. 2014;2:e116.

69. Speziale M, et al. Cardiovascular risk for workers in big, infrastructure projects. Occup Med Health Aff. 2014;2:175.

70. Haidinger T, et al. Influence of migration status and gender on awareness of cardiovascular risk factors and cardiovascular health in a group of Turkish immigrants and indigenous Austrians. J Gen Practice. 2014;2:169.

71. Janda K, et al. Risk stratification in dialysis patients: Coronary artery calcification score combined with high sensitive c-reactive protein and framingham score for cardiovascular risk prediction in asymptomatic subjects. J Clin Exp Cardiolog. 2014;5:296.

72. Mikirova N, et al. Effects of micronutrient supplementation on concentrations of vitamins and minerals, inflammation and cardiovascular risk factors. Vitam Miner. 2014;3:120.

73. Piepoli MF, et al. Secondary prevention through cardiac rehabilitation: From knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. European Journal of Cardiovascular Prevention & Rehabilitation. 2010;17:1-7.

74. Staessen JA, et al. Blood pressure reduction and cardiovascular prevention: An update including the 2003–2004 secondary prevention trials. Hypertension research. 2005;28:385-407.

75. Topol EJ. Intensive statin therapy-a sea change in cardiovascular prevention. New England Journal of Medicine. 2004;350:1562-1564.

76. Capewell S, et al. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart. 1999;81:380-386.

77. Hobbs FR, et al. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: The Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Family practice. 2002;19:596-604.

78. Fearnot NE. Implantable cardiovascular treatment device container for sensing a physiological parameter. United States patent US 5,040,533. 1991.

79. Musselman DL, et al. The relationship of depression to cardiovascular disease: Epidemiology, biology and treatment. Archives of general psychiatry. 1998;55:580-592.

80. Trialists'Collaboration BP. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410-1419.

81. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA. 1996;275:1571-1576.

82. Thompson PD, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation and Prevention) and the Council on Nutrition, Physical Activity and Metabolism (Subcommittee on Physical Activity). Circulation. 2003 ;107:3109-3116.

83. Kaufman LE, et al. The potential impact of nuclear magnetic resonance imaging on cardiovascular diagnosis. Circulation. 1983;67:251-257.

84. Frommer PL, et al. The use of ascorbate dilution curves in cardiovascular diagnosis applications of a technic for direct intravascular detection of indicator. Circulation. 1961;24:1227-1234.

85. Falcone C, et al. Cardiovascular risk factors and sympatho-vagal balance: Importance of timedomain heart rate variability. J Clin Exp Cardiolog. 2014;5:289.

86. Voloshyna I, et al. Advanced glycation end products promote pro-atherogenic changes in cholesterol transport: A possible mechanism for cardiovascular risk in diabetes. Intern Med. 2014;S11:005.

87. Agamia NF, et al. Evaluation of soluble P-selectin and leptin serum levels in sera of patients of psoriasis and their possible role in the increase in the cardiovascular risks in psoriatic patients. J Clin Exp Dermatol Res. 2014;5:201.

88. Joshi H, et al. Prevalence of vitamin D deficiency among post-menopausal women and associated obesity and cardiovascular risk. J Obes Weight Loss Ther. 2013;3:192.

89. Baragou S, et al. Cardiovascular risk factors in black African obese patients: A multicentric comparative study in 1512 patients in Lome (Togo). J Obes Weight Loss Ther. 2013;3:184.

90. Holstad MMD, et al. The impact of a health promotion educational program on cardiovascular risk factors for HIV infected women on antiretroviral therapy. J AIDS Clin Res. 2013;4:224.

91. Sauvageot N, et al. Validation of the food frequency questionnaire used to assess the association between dietary habits and cardiovascular risk factors in the NESCAV study. J Nutr Food Sci. 2013;3:208.

92. Sufi F, et al. Novel methods of faster cardiovascular diagnosis in wireless telecardiology. IEEE Journal on Selected Areas in Communications. 2009;27:537-552.

93. Manninen P, et al. Cardiovascular signs of acute hypoxaemia and hypercarbia during enflurane and halothane anaesthesia in man. Canadian Anaesthetists' Society Journal. 1979;26:282-287.

94. Gutgesell HP, et al. Common cardiovascular problems in the young: Part I. Murmurs, chest pain, syncope and irregular rhythms. American Family Physician. 1997;56:1825-1830.

95. Neves MDF, et al. Prevalence of cardiovascular risk factors on different phases of diabetic nephropathy in comparison to type 1 diabetes recipients who had undergone simultaneous pancreas kidney transplant. J Diabetes Metab. 2013;S9:002.

96. O'Neil CE, et al. Mangoes are associated with better nutrient intake, diet quality and levels of some cardiovascular risk factors: National Health and Nutrition Examination Survey. J Nutr Food Sci. 2013;3:185.

97. Radellini C, et al. Ankle- brachial index as a predictor of cardiovascular risk in atrial fibrillation. J Clin Exp Cardiolog. 2012;3:224.

98. Qureshi AA, et al. Suppression of nitric oxide production and cardiovascular risk factors in healthy seniors and hypercholesterolemic subjects by a combination of polyphenols and vitamins. J Clin Exp Cardiolog. 2012;S5:008.

99. Barclay BL, et al. Dosage form for administering nilvadipine for treating cardiovascular symptoms. United States Patent US 4,902,514. 1990.

100. Cederl R, et al. Cardiovascular and respiratory symptoms in relation to tobacco smoking: A study on American twins. Archives of Environmental Health: An International Journal. 1969;18:934-940.